On the basis of transcriptomic analyses, TME of NSCLC is categorized into the immunity-high, immunity-medium, and immunity-low subtypes (30–32), and proteogenomic analysis of LUAD identified three major clusters (hot, cold-tumor enriched, and cold-NAT enriched; ref. 33). The gene discussed is BRD2; the disease is non-small cell lung carcinoma.